Mergers and Innovation in the Pharmaceutical Industry
27 Pages Posted: 17 Dec 2012
Date Written: December 3, 2012
Abstract
Conflicting trends confound the pharmaceutical industry. The productivity of pharmaceutical innovation has declined in recent years. At the same time, the cohort of large companies who are the leading engines of pharmaceutical R&D has become increasingly concentrated. The concurrent presence of these trends is not sufficient to determine causation. In response to lagging innovation prospects, some companies have sought refuge in mergers and acquisitions to disguise their dwindling prospects or gain R&D synergies. On the other hand, the increased concentration brought on by recent mergers may have contributed to the declining rate of innovation. In this paper, we consider the second of these causal relationships: the likely impact of the recent merger wave among the largest pharmaceutical companies on the rate of innovation. In other words, have recent mergers, which may have been taken in response to lagging innovation, represented a selfdefeating strategy that only made industry outcomes worse?
Keywords: Pharmaceutical Mergers, Innovation
Suggested Citation: Suggested Citation
Do you have negative results from your research you’d like to share?
Recommended Papers
-
By Bronwyn H. Hall, Jacques Mairesse, ...
-
By Bronwyn H. Hall, Jacques Mairesse, ...
-
One or Many Knowledge Production Functions? Mapping Innovative Activity Using Microdata
By Andrea Conte and Marco Vivarelli
-
By M. Ishaq Nadiri and Ingmar R. Prucha
-
Corporate Taxation and the Choice of Patent Location within Multinational Firms
By Tom Karkinsky and Nadine Riedel
-
On the Relationship between R&D and Productivity: A Treatment Effect Analysis
By Giuseppe Medda, Claudio A. Piga, ...